Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,245

Document Document Title
WO/2022/109469A1
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). ...  
WO/2022/068915A1
Provided are a 6-oxo-1,6-dihydropyridazin derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a 6-oxo-1,6-dihydropyridazin derivative as shown by general formu...  
WO/2022/059700A1
The present invention provides a triazine compound salt that has an aldosterone synthase inhibitory effect and is useful as a medicine, in particular, an agent for preventing or treating primary aldosteronism and the like, a crystal, and...  
WO/2022/053028A1
Disclosed are a series of 1,2,4-triazine-3,5(2H,4H)-diketone compounds and an application thereof. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.  
WO/2022/037650A1
Provided herein are bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts, which are as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. Also provided are methods for preparing Compounds A and B o...  
WO/2022/037617A1
A compound represented by structural formula (I) and a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing them, capable of being used as agonists of a thyroid hormone receptor -β, capable of being used ...  
WO/2022/031838A1
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...  
WO/2022/026285A1
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing influenza. The compounds are cap-dependent en...  
WO/2022/007752A1
The present invention relates to the field of chemical medicines, and particularly to a new crystal form of a free base and dihydrochloride of benzamide compounds, and a preparation method therefor. Provided in the present invention are ...  
WO/2022/006433A1
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...  
WO/2021/228734A1
The present disclosure relates to triazine and pyrimidine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.  
WO/2021/224680A1
Compounds that are mammalian metabolites of an agonist of G-protein-coupled receptor 1.39 (GPR139), intermediates used in the synthesis of such metabolites, pharmaceutical compositions comprising such metabolites, and the use of such met...  
WO/2021/186406A1
The present invention provides a co-crystal of sulfentrazone and a triazinone herbicide and process for preparation thereof. The present invention also provides an agrochemical composition comprising said co-crystal and process of prepar...  
WO/2021/165818A1
The present invention relates to a novel chemical process for the synthesis of the compound 2- fluoro-N-methyl-4-[7-quinolin-6-yl-methyl)-imidazo[1,2-b][1, 2,4]triazin-2yl]benzamide.  
WO/2021/143706A1
The application relates to a compound of Formula (I') or (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutica...  
WO/2021/117809A1
According to the present invention, a light-emitting material formed from a compound comprising a naphthotriazole structure and/or a naphthotriazine structure has superior light-emitting properties.  
WO/2021/096948A1
The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, incl...  
WO/2021/093377A1
In order to improve the device performance of an organic electroluminescent device, particularly the light extraction efficiency, the present application provides an organic electroluminescent device comprising a light extraction layer, ...  
WO/2021/057791A1
Provided are a chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further comprising a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be u...  
WO/2021/043185A1
Provided herein is a compound as a thyroid hormone β receptor agonist and use thereof. It further relates to a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used in the manufac...  
WO/2021/032648A1
Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease.  
WO/2020/251972A1
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamil...  
WO/2020/249428A1
A process for the manufacture of ethyleneamines and ethanolamines, comprising the steps of (i) converting a glycolaldehyde derivative of formula (II), in which R2, R3 are - the same or different -hydrogen, alkyl, such as C1-6-alkyl, or c...  
WO/2020/251974A1
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamil...  
WO/2020/239105A1
The present invention provides a novel method for synthesizing metribuzin, comprising the following steps: 1) adding 6-tert-butyl-4-amino-3-mercapto-1,2,4-triazine-5(4H)-ketone to a certain amount of sulfuric acid in batches, and heating...  
WO/2020/225569A1
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally s...  
WO/2020/221276A1
The present invention relates to a salt of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-dia mine and a solid form thereof, a method for preparing the solid form and a pharmaceutical composition comprising the solid form, as w...  
WO/2020/206583A1
This invention described herein relates to compounds of general formula (I) : (I), in which variable groups are as defined herein, and to their preparation and use. Uses for the compounds and for compositions containing them include trea...  
WO/2020/201460A1
A multicomponent crystal (or co-crystal) comprising a first active pharmaceutical ingredient and a second active pharmaceutical ingredient. The multicomponent crystal is formed / sustained by non- covalent interactions between the nitrog...  
WO/2020/169069A1
A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds ...  
WO/2020/157189A1
The present invention includes name compounds of general formula (I) in which R1, Y, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical composi...  
WO/2020/157194A1
The present invention includes name compounds of general formula (I) : (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their...  
WO/2020/144093A1
The presently claimed invention relates to a novel, highly efficient and general process for the preparation of the triazine intermediates and their use in the preparation of UV absorbers.  
WO/2020/077123A1
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by TH...  
WO/2020/051207A2
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...  
WO/2020/011220A1
A heteroaryl derivative represented by general formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative and a use thereof as a therapeutic agent, in particular as an A2a receptor and/or an A2...  
WO/2020/009971A1
The present application provides, inter alia, a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, and R6 are as described herein. Methods of making these compounds and m...  
WO/2020/005935A1
This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are us...  
WO/2019/243823A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.  
WO/2019/218797A1
Provided is a compound, characterized in being a compound as shown in the following structure: The novel small molecule compound synthesized by the present invention, when applied for external use, can be used for promoting hair regrowth...  
WO/2019/167982A1
The present invention pertains to: a saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound having RORγ antagonist activity or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing same;...  
WO/2019/158070A1
A heterocyclic compound as an A2A and/or A2B receptor antagonist. Specifically, provided is a compound as represented by the following formula I, wherein each group is as defined in the description. The compound has A2A and/or A2B inhibi...  
WO/2019/141552A1
The present invention relates to the triazine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of triazine compounds of f...  
WO/2019/122932A1
Compounds of general formula (I): (Formula (I)) wherein R1, R2, X1 and X2 are as defined herein are useful for the treatment of cancer, particularly solid tumours.  
WO/2019/056247A1
The present invention belongs to the technical field of pesticides, and in particular relates to a triazinone derivative containing an acylhydrazone structure and a preparation method therefor, and insecticidal and bactericidal uses ther...  
WO/2019/040394A1
The present disclosure is directed to non-corrosive cleaning compositions that are useful, e.g., for removing residues (e.g., plasma etch and/or plasma ashing residues) and/or metal oxides from a semiconductor substrate as an intermediat...  
WO/2019/028272A1
Disclosed herein are compositions and methods for stabilizing a benzothiazole luciferin analog such as D-luciferin and 6-amino-D-luciferin. The compositions may include the benzothiazole luciferin analog, a thionucleobase compound of for...  
WO/2018/226923A1
An antimicrobial compound comprising 1, 3, 5-triazine core substituted with quinoline or imidazolidine-2, 4-dione.  
WO/2018/208123A1
The present invention relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1...  
WO/2018/148745A1
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, ab...  

Matches 1 - 50 out of 1,245